1. Home
  2. THRD vs MSD Comparison

THRD vs MSD Comparison

Compare THRD & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THRD
  • MSD
  • Stock Information
  • Founded
  • THRD 2019
  • MSD 1993
  • Country
  • THRD United States
  • MSD United States
  • Employees
  • THRD N/A
  • MSD N/A
  • Industry
  • THRD Biotechnology: Pharmaceutical Preparations
  • MSD Trusts Except Educational Religious and Charitable
  • Sector
  • THRD Health Care
  • MSD Finance
  • Exchange
  • THRD Nasdaq
  • MSD Nasdaq
  • Market Cap
  • THRD 164.2M
  • MSD 144.6M
  • IPO Year
  • THRD 2022
  • MSD N/A
  • Fundamental
  • Price
  • THRD $5.14
  • MSD $7.65
  • Analyst Decision
  • THRD Hold
  • MSD
  • Analyst Count
  • THRD 3
  • MSD 0
  • Target Price
  • THRD $5.00
  • MSD N/A
  • AVG Volume (30 Days)
  • THRD 1.2M
  • MSD 70.2K
  • Earning Date
  • THRD 05-14-2025
  • MSD 01-01-0001
  • Dividend Yield
  • THRD N/A
  • MSD 11.26%
  • EPS Growth
  • THRD N/A
  • MSD N/A
  • EPS
  • THRD N/A
  • MSD N/A
  • Revenue
  • THRD N/A
  • MSD N/A
  • Revenue This Year
  • THRD N/A
  • MSD N/A
  • Revenue Next Year
  • THRD N/A
  • MSD N/A
  • P/E Ratio
  • THRD N/A
  • MSD N/A
  • Revenue Growth
  • THRD N/A
  • MSD N/A
  • 52 Week Low
  • THRD $3.18
  • MSD $6.11
  • 52 Week High
  • THRD $16.94
  • MSD $7.46
  • Technical
  • Relative Strength Index (RSI)
  • THRD 79.10
  • MSD 51.13
  • Support Level
  • THRD $5.08
  • MSD $7.20
  • Resistance Level
  • THRD $5.20
  • MSD $7.52
  • Average True Range (ATR)
  • THRD 0.11
  • MSD 0.20
  • MACD
  • THRD 0.13
  • MSD 0.05
  • Stochastic Oscillator
  • THRD 96.84
  • MSD 91.36

About THRD Third Harmonic Bio Inc.

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

About MSD Morgan Stanley Emerging Markets Debt Fund Inc.

Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.

Share on Social Networks: